Communities observe National Prevention Week
Each year, National Prevention Week aims to address many of the underlying factors that can lead to substance use issues.
Prevention Week is an opportunity to raise awareness of substance misuse and mental health issues, and to collaborate on creating effective solutions and resources according to the U.S. Drug Enforcement Administration.
Chairperson for the Mercer County Coalition for Healthy Communities Candace Harless said that early prevention can affect everything from mental and physical health to social and financial status.
'Early prevention helps individuals live healthier lives, more stable lives and have better relationships, education and employment outcomes,' Harless told 59News.
One crucial aspect of prevention comes in the form of connection and community involvement, factors that can decrease risk for substance use and mental health issues, according to Fayette County Health Department Prevention Coordinator, Katie Johnson.
'We know that boredom or lack of success are a couple of reasons that kids experiment with drugs,' she said.
National Prevention Week will be observed from May 12 – May 17, offering a prime opportunity for folks to get involved and get educated on prevention.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
12 hours ago
Beshear bans drug in Kentucky that's being targeted by attorneys general across the nation
FRANKFORT, Ky. -- Kentucky Gov. Andy Beshear took emergency action Monday to ban the sale of 'designer Xanax,' responding to a request from his state's attorney general who is leading a broader effort to combat the highly potent synthetic drug linked to dozens of overdose deaths last year in the Bluegrass State. Beshear's action in his state comes as a coalition of 21 attorneys general, led by Kentucky Attorney General Russell Coleman, is urging the U.S. Drug Enforcement Administration to take emergency action banning the unregulated drug. It poses a growing public health threat and is increasingly contributing to overdose deaths, the attorneys general said in a letter dated Monday to DEA Administrator Terry Cole. 'Law enforcement desperately needs the tools to drive this dangerous drug from our neighborhoods,' Coleman, a Republican, said in a news release. In Kentucky, the classification of bromazolam — widely known as 'designer Xanax' — as a Schedule 1 controlled substance took immediate effect following Beshear's emergency regulation. Bromazolam, Coleman has warned, is being passed off as prescription pills including benzodiazepines, which are commonly used to treat conditions such as anxiety disorders, insomnia, and seizures. He had urged Beshear's administration to ban the drug in Kentucky, and the governor's action on Monday empowers law enforcement to make arrests for selling or possessing the drug, Beshear's office said. 'This deadly drug has no place in our communities, and now we have the tools needed to get it off the streets and protect more lives,' the Democratic governor said in a release. Beshear, a former Kentucky attorney general now in his second term as governor, is widely seen as a potential candidate for president in 2028. The drug he and Coleman targeted has been tied to a growing number of fatal overdoses in Kentucky and across the nation, Beshear's office said. It was detected in nearly 50 overdose deaths in Kentucky last year, the office said. 'We live in a moment when as little as one pill can kill – and is killing – our kids,' Coleman said in response to Beshear's action. "I'm glad we could work together to tackle this grave threat.' In their letter to the head of DEA, the attorneys general said bromazolam is being sold illicitly on the streets and online. It is highly potent and unpredictable, they said, especially when combined with opioids or other central nervous system depressants. Unlike regulated medications, illicitly manufactured bromazolam lacks quality controls, making it particularly lethal for unsuspecting users, they said. 'Despite its clear dangers, bromazolam remains unscheduled at the federal level, creating significant challenges for law enforcement and public health officials trying to respond to this emerging crisis,' the letter said. 'Without scheduling, this drug continues to evade traditional regulatory and prosecutorial tools, hindering interdiction efforts and enabling continued distribution through illicit channels.' Emergency action by the DEA would help law enforcement remove the drug from circulation, give prosecutors the ability to hold traffickers accountable and would 'send a clear signal that this dangerous substance has no place on our streets,' the letter said. Besides Coleman, the request to the DEA included attorneys general from Alabama, Arkansas, Florida, Georgia, Indiana, Iowa, Louisiana, Mississippi, Montana, Nebraska, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Virginia and West Virginia, Coleman's office said.
The Hill
09-08-2025
- The Hill
Should marijuana be rescheduled?
For more than 50 years, dozens of 'controlled substances,' including various pharmaceutical products as well as marijuana, cocaine, heroin and everything in between, have been shoe-horned into five statutory 'Schedules,' according to various criteria set in federal law. While some of these categorizations make sense, others do not. Marijuana (technically, tetrahydrocannabinols or THC, which is the operative chemical in the marijuana plant) falls into the latter category — and perhaps it's time to revisit this aspect of the 'Controlled Substance Schedules.' THC is currently classified at the highest level, that is, as a Schedule I controlled substance — on par with heroin and LSD and having ' no currently accepted medical use.' Even those of us who don't think recreational marijuana use is a good idea can agree that the current scheduling is absurd and erodes institutional trust. Frankly, it is time to reschedule cannabis to where it belongs — Schedule III — which will still limit its availability but also will allow for expanded medical research into therapeutic uses of the drug and restore common sense to federal drug policy. Most people surely recognize that cannabis — whatever they think its legal status should be — is a far cry from heroin and does not belong in the same enforcement category. In contrast, even cocaine is less restricted, categorized as Schedule II. As someone who cares about the rule of law, I know how insidious it is to maintain such clearly nonsensical regulations. It undermines the broader credibility of federal drug scheduling. This anomaly is compounded by the reality that a large majority of states — 40 states, three territories, and the District of Columbia — currently recognize medical uses for cannabis. In other words, most states now contradict the federal position that there is 'no accepted medical use' for cannabis. This tension can be largely resolved without going so far as to legalize recreational use on the federal level. The U.S. Drug Enforcement Administration defines Schedule III drugs as having a moderate to low potential for physical and psychological dependence. Schedule III currently includes anabolic steroids, testosterone and ketamine, to name a few. Cannabis would fit far more sensibly in that list. Rescheduling cannabis is not merely a bureaucratic reshuffling. Its Schedule I status creates major barriers for researchers and doctors wishing to study potential therapeutic uses. Further, it creates burdensome red tape that slows scientific progress. It demonstrably is not the case that no medical value can be had from marijuana. It has been used effectively to help patients with epilepsy, chronic pain, PTSD and chemotherapy-induced nausea. The notion that there is no known medical use for cannabis and cannabis-derived medication is clearly outdated. As a conservative, I have always believed that cutting regulatory red tape spurs economic growth. This would be the case for rescheduling cannabis; a straightforward change would support more than 440,000 existing jobs and open the door to future growth. It would lead to more American jobs in research and medicine, generating therapeutic breakthroughs and boosting the economy. If the Trump administration moves forward with cannabis rescheduling, it is critical that they do it the right way. I've spent enough time in Washington to know that stuffing such a change into an omnibus spending bill is not the answer. Nor is an executive order the right vehicle for this policy shift, since rescheduling could easily be undone by a future administration. Instead, the federal government should reschedule cannabis via the official rulemaking process, which would involve the Drug Enforcement Administration and the Department of Justice in coordination with the White House and other executive branch stakeholders. Taking an objective view of the current cannabis policy landscape, it is clear that both scientific and cultural attitudes about marijuana have progressed dramatically in recent years. It is time for the federal government to catch up. Rescheduling marijuana to a Schedule III controlled substance is a substantive but nuanced way to do so without legalizing the drug wholesale. Ultimately, cannabis is a drug that can have genuine medical benefits and its therapeutic uses warrant further research. Rescheduling marijuana to a more sensible classification will unlock new research, new jobs and help restore credibility to federal drug laws. Bob Barr represented Georgia's 7th District in the U.S. House of Representatives from 1995 to 2003. He served previously as the United States Attorney in Atlanta from 1986 to 1990 and was an official with the CIA in the 1970s. He now practices law in Atlanta, serves as head of Liberty Guard, and is the immediate past president of the National Rifle Association of America.
Fox News
05-08-2025
- Fox News
Deadly drug stronger than fentanyl spreads rapidly across the Americas, experts warn
A little-known opioid that's deadlier than fentanyl has led to a growing number of overdose deaths in recent years. Nitazenes, a class of synthetic opioids, were originally developed as pain relievers in the 1950s, but were never approved for use due to the high overdose risk, according to a report from the Inter-American Drug Abuse Control Commission (CICAD). Starting in 2019, nitazenes (benzimidazole-opioids) began to enter the illicit drug market in Europe, where they have been reported on almost every continent. CICAD's report suggests that "nitazene use is a growing trend in North America and that availability is likely spreading across the Americas." The most prevalent type of nitazene is isotonitazene (ISO), but at least a dozen others have been identified, the report stated. The U.S. Drug Enforcement Administration (DEA) classifies ISO as a Schedule 1 drug, along with seven other nitazenes. "Nitazenes are being produced in illicit labs overseas, mostly in places like China and India, and are getting trafficked into the U.S. through the same channels used for fentanyl," Corey Gamberg, a licensed alcohol and drug counselor and executive director at the Massachusetts Center for Addiction, told Fox News Digital. Because they're synthetic and cheap to make, they've become a popular option for illegal manufacturers, the expert noted. "As authorities crack down on fentanyl, traffickers pivot to new synthetic opioids like nitazenes to get around enforcement," Gamberg went on. "These drugs are cheap to make and easy to move. It's a pattern we've seen before, and it's repeating itself now." Nitazenes are available in pills, powders, sprays and other forms. They can be snorted, smoked, injected or taken orally. The biggest risk is potency, as some types of nitazenes are several times stronger than fentanyl. "These drugs are cheap to make and easy to move. It's a pattern we've seen before, and it's repeating itself now." Dr. Jonathan Avery, vice chair of addiction psychiatry at NewYork-Presbyterian/Weill Cornell Medical Center, confirmed that nitazenes can be hundreds of times stronger than morphine and up to 10 times more potent than fentanyl, "making even tiny doses deadly." In addition to potentially fatal overdoses, the drugs are known to cause dependency, dizziness, nausea, vomiting, disorientation, loss of consciousness, cardiac arrest and seizures, according to the CICAD report. The other issue is that people usually don't know they're taking them. "Nitazenes are often mixed into heroin, pressed pills or even stimulants — so someone might think they're using one thing and end up taking something completely different," Gamberg cautioned. "That unpredictability is what makes them so deadly." Adding to the danger of nitazenes is that testing is very limited, according to Dr. Ryan Marino, a medical toxicologist at Case Western University in Cleveland, Ohio. "Test strips are available that can help people screen things like powdered drugs and pills for the presence of nitazenes, but more definitive testing is limited to more advanced toxicology labs, and also limited by cost and turnaround time," he told Fox News Digital. "While test strips are useful, they are not a definitive way to rule out nitazenes in drugs, and more advanced testing for nitazenes is not widely available, even in post-mortem testing." Routine hospital and workplace drug screens do not reliably detect nitazenes, according to Avery. "Enforcement is difficult because producers constantly tweak chemical structures to evade laws and standard tests," he said. To prevent deadly overdoses, Avery called for specialized testing and rapid drug‑checking tools to identify nitazenes in the street supply. For more Health articles, visit "Naloxone (Narcan) can reverse nitazene overdoses, but multiple doses may be needed because of their potency," he said. "Public awareness, widespread naloxone distribution and rapid drug‑checking are key to preventing deaths."
